Reports in pancreatic cancer and bone osteosarcoma indicate that alpha mangostin was able to suppress EMT.15,16 Studies on alpha mangostin in HepG2 cells have been done before by Wudtiwai et al and Mohamed et al.17,18 However, none have investigated the effect of alpha mangostin in EMT through TGF-β/Smad pathways in the sorafenib-surviving liver carcinoma model. Here, TGFB1 is linked to hepatocellular carcinoma.